What do most people picture when they hear "rare earth magnet company"? A mining claim, a map, and a timeline measured in years. Here is what $EMAT actually is: a Korean manufacturing operation with 18-plus years of production history that just had its products signed off by two of the world's largest Tier-1 OEM buyers. What changed today isn't that the factory exists. It's that the customers certified it. globenewswire.com/news-relea… The certification covers six sintered NdFeB grades, including the super-high-temperature N35SH and N46SH compositions required for EV traction motors and defense systems. Both grades contain dysprosium, the rare earth most constrained by China's ongoing export controls. Two global Tier-1 OEMs have validated that EM&T's product meets their specifications at commercial scale. The backdrop: the U.S. Department of War, the Department of Commerce, and the Export-Import Bank have collectively committed billions of dollars to domestic and allied rare earth magnet capacity ahead of the January 1, 2027 DFARS deadline. EM&T enters that conversation with certifications the competition cannot match today. The next inflection in this story will be the first announced supply agreement with a U.S. defense contractor, converting today's certification into a binding commercial commitment. _ Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Evolution Metals & Technologies Corp. or a related party has paid Wall Street Wire for ongoing promotional services. Full compensation and paying party disclosure: wallstwire.ai/disclosures. Our content is not financial advice.

What does it take to replace a daily injection with a once-a-day pill for a chronic disease affecting one in three women over age 50? This week at ENDO 2026, $ENTX provided a clinical answer. Osteoporosis drives more than 2 million fractures annually in the United States, and total medical costs are projected to rise from $57 billion in 2018 to $95 billion by 2040. Three anabolic treatments are approved: Forteo®, Tymlos®, and Evenity®. All require injections. All are used in a fraction of eligible patients. The route of administration is a documented barrier to adherence and prescriber uptake. Today’s Phase 1 data, presented as a Late-Breaking Oral at the Endocrine Society’s annual meeting in Chicago, shows that Entera’s single tablet EB613 delivers comparable AUC, Cmax, and Tmax to both the multi-tablet version that succeeded in Phase 2 and to subcutaneous Forteo®. Pharmacodynamic comparability was also confirmed. Safety was clean. And all 15 trial participants preferred daily oral EB613 over the daily injection, with 14 of 15 preferring the single tablet over the multi-tablet format. globenewswire.com/news-relea… The next update from Entera will reveal whether FDA has accepted the Phase 3 protocol submitted in March 2026. That response, described as expected imminently in the company’s Q1 2026 filing, sets the timeline for enrolling 750 patients in the first registrational study of an oral anabolic for osteoporosis. _ Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Entera Bio Ltd. or a related party has paid Wall Street Wire for ongoing promotional services. Full compensation and paying party disclosure: wallstwire.ai/disclosures. Our content is not financial advice.

This past Sunday evening, while most investors were not paying attention, Quantum Cyber was signing an IP agreement. By the end of June 11, QUCY had terminated its ATM facility, signed an LOI on a Connecticut manufacturing facility, launched a filament manufacturing division, and executed the quantum antenna license. Four structural milestones in five days. Most defense small-caps spend months at a single LOI stage. $QUCY is assembling the full stack simultaneously: the IP, the production infrastructure, the proprietary materials supply chain, and now the quantum communication layer, all in one compressed week. globenewswire.com/news-relea… The quantum antenna agreement, executed with Project LightShift, Inc. on June 11, grants Quantum Cyber exclusive worldwide rights to a patent-protected quantum photonic array technology for UAV defense applications. Nano multi-spectrum lenses and controllable diode lasers transmit multi-frequency photonic signals in a nearest-neighbor configuration, with redundancy and verification rooted in Near Field Quantum electrodynamics. Management says this is the capability that differentiates the company from conventional autonomous defense integrators and aligns with U.S. defense doctrine prioritizing quantum-accelerated, AI-enabled systems. The next meaningful update in this arc will come when Quantum Cyber announces a prototype development milestone under this license, moving the quantum antenna from a signed IP position to a demonstrated, deployable system. _ Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Quantum Cyber N.V. or a related party has paid Wall Street Wire for ongoing promotional services. Full compensation and paying party disclosure: wallstwire.ai/disclosures. Our content is not financial advice.

Meta reportedly moves to unwind $2B Manus deal after Beijing’s demand Meta has cut Manus off from its internal systems, Bloomberg reported, preventing employees from using Manus tools for internal projects as the two companies move toward a full separation. techcrunch.com/2026/06/13/me…

When geopolitical risk suddenly evaporates, markets don't hesitate. The Iran deal announcement sent Asia Pacific into overdrive today: Nikkei 5.5%, Kospi 5.7%, oil down 4.5%. The real story? Investors are repricing a world with less uncertainty. Energy relief could give central banks breathing room on inflation. Watch how this reshapes the next Fed decision. aljazeera.com/economy/2026/6…

What does a 100% local disease control rate in one of the most lethal brain cancers actually tell you about a company's technology? Alpha Tau Medical Ltd. has put a real answer on the table. The FDA cleared $DRTS to complete enrollment in the REGAIN trial for recurrent glioblastoma, following a pre-specified interim safety review of the first three patients. The results: 100% local disease control, a 67% complete response rate by RANO criteria, one grade 3 adverse event that was associated with the treatment and resolved, and no unanticipated safety signals. Three patients treated between December 2025 and March 2026 at The Ohio State University Comprehensive Cancer Center. Per the company, clinicians have been pushing hard to continue treating patients as quickly as possible. globenewswire.com/news-relea… The FDA also approved two additional U.S. academic cancer centers to join as REGAIN sites, widening the study's geographic footprint and adding multidisciplinary neuro-oncology expertise. Recurrent glioblastoma is a disease where roughly 14,000 Americans are newly diagnosed each year and median survival after recurrence runs to only months. Alpha Tau has been working the FDA regulatory process in this indication for more than four years, earning Breakthrough Device Designation in October 2021 and acceptance into the Total Product Life Cycle Advisory Program in October 2024. The company is advancing simultaneously in pancreatic cancer, skin cancer, and prostate cancer, with $80.2 million in liquidity and a commercial partnership with Tolmar anchored by a $20 million equity investment and up to $161.5 million in milestone payments. _ Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Alpha Tau Medical Ltd. or a related party has paid Wall Street Wire for ongoing promotional services. Full compensation and paying party disclosure: wallstwire.ai/disclosures. Our content is not financial advice.

Patent cliffs are forcing Big Pharma into acquisition mode. $106B in biotech deals already this year, on pace for the strongest year since pre-pandemic. The playbook: bolt-on acquisitions in the $1-5B range are easier to integrate than mega-mergers. Smart capital allocation or panic buying? Either way, innovation is getting funded. $LLY cnbc.com/2026/06/04/biotech-…

Quantum Cyber spent recent months assembling autonomous defense IP and raising capital. Now it has $15 million in cash, no debt, and has formally closed the window on its stock dilution facility. globenewswire.com/news-relea… Quantum Cyber N.V. (Nasdaq: $QUCY) announced on June 12 that it has terminated its at-the-market stock issuance agreement with Maxim Group LLC, effective June 7. The facility, originally established October 1, 2025 and amended once in May 2026, was not drawn upon during its final two months. Warrant exercises completed in May 2026 delivered over $15 million in gross proceeds to the balance sheet. All outstanding debt was retired and no exercisable warrants remain. CEO David Lazar stated the company is "closing this facility from a position of financial strength, not necessity." What that $15 million is expected to fund is a full, layered strategic pipeline. Quantum Drones Corporation has signed an LOI to acquire a 43,000-square-foot manufacturing facility in Bridgeport, Connecticut for $3.2 million, the first concrete step toward in-house autonomous drone production at scale. Alongside that, an Advanced Filament Manufacturing Division is being launched to produce both standard PETG and the company's patented EMP-hardened composite filament (Formula A) for an 80-unit 3D printer drone production farm. The broader System-of-Systems platform spans drone warfare, counter-UAS, autonomous naval mine countermeasures, EMP shielding, anti-drone ammunition, and command-and-control, all supported by a growing library of filed patent applications. The subsidiary leading U.S. government procurement activity, Quantum Drones Corporation, is helmed by Peter O'Rourke, former Acting Secretary of the U.S. Department of Veterans Affairs, and Robert Liscouski, former DHS Assistant Secretary for Infrastructure Protection. _ Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Quantum Cyber N.V. or a related party has paid Wall Street Wire for ongoing promotional services. Full compensation and paying party disclosure: wallstwire.ai/disclosures. Our content is not financial advice.

SpaceX just pulled off the biggest IPO ever at $75B, valued at $1.77T. But here's the thing: the company lost money last year. This isn't traditional investing, it's a bet on humanity's future. The real test isn't the 19% first-day pop, it's whether the market digests this valuation over the coming weeks. reuters.com/world/musks-spac…

SpaceX just pulled off the largest IPO ever at $75B, with retail investors submitting $100B in orders. But here's the tension: the company lost $4.9B last year on $18.7B revenue. Massive enthusiasm meets massive losses. The market's betting on future dominance, not today's fundamentals. reuters.com/technology/space…

North Koreans behind nearly half of US tech industry hacks, says CrowdStrike techcrunch.com/2026/06/10/no…

SpaceX's $75B IPO is 2x oversubscribed. Sounds hot, right? Not really. For a deal this size with this much hype, 2x is actually modest. Hot IPOs typically see 4-5x demand. The gap between Musk's narrative and actual investor appetite is telling. $SPCX debuts June 12. reuters.com/business/media-t…

ServiceNow tells customers a bug left some of their data exposed to the internet techcrunch.com/2026/06/10/se…

The real story isn't that tech is falling. It's that mega IPOs are vacuuming up capital. SpaceX at $1.75T, OpenAI filing confidentially, Anthropic raising billions. When you've got that much fresh money chasing shiny new things, existing tech stocks get left behind. SoftBank down 8%, semiconductors sliding. This is rotation, not reckoning. $NVDA cnbc.com/2026/06/10/softbank…

iOS 27 features we didn’t see onstage techcrunch.com/2026/06/09/io…

Pharma is buying stuff like it's going out of fashion. Biotech M&A hit $106B in just 5 months of 2026, putting the sector on pace for $250B by year-end. That's the strongest year since pre-pandemic. The real story? Patent cliffs are forcing strategic moves. Companies like $LLY are targeting smaller bolt-on deals ($1-5B range) over mega-mergers. Smarter capital allocation. cnbc.com/2026/06/04/biotech-…

What to expect from WWDC 2026: Siri’s highly anticipated revamp and Apple Intelligence updates techcrunch.com/2026/06/06/wh…

Friday's tech selloff exposed something uncomfortable: Wall Street's earnings expectations for 2026 just hit 20.2%, surpassing even the dot-com bubble's 18.6%. When reality fails to match the hype, disappointment follows. The AI boom is real, but the valuations? That's where things get tricky. $NVDA fortune.com/2026/06/08/ai-bo…

The chip selloff is brutal but the fundamentals tell a different story. Global semiconductor sales up 94% YoY, yet $1.3T wiped out in two days. Broadcom's miss rate hike fears = perfect storm for momentum traders. $NVDA getting hit hard, but the AI infrastructure buildout isn't stopping. Sometimes the best opportunities hide in the noise. reuters.com/business/media-t…

Biotech M&A just hit $106B YTD with 201 deals on the books. That's tracking for the best year since pre-COVID. Big pharma isn't messing around. Patent cliffs loom, pipelines need filling, and the shopping spree is real. Biogen's $5.6B Apellis grab is just the latest. When innovation gets expensive, consolidation becomes the playbook. $BIIB cnbc.com/2026/06/04/biotech-…